Notable Mover: BioDelivery Sciences International, Inc.’s Trend Up, Especially After Today’s Strong Session


Notable Mover: BioDelivery Sciences International, Inc.'s Trend Up, Especially After Today's Strong Session

The stock of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) is a huge mover today! About 292,706 shares traded hands. BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has declined 15.47% since March 15, 2016 and is downtrending. It has underperformed by 20.95% the S&P500.
The move comes after 8 months positive chart setup for the $129.24M company. It was reported on Oct, 18 by We have $4.25 PT which if reached, will make NASDAQ:BDSI worth $96.93M more.

Analysts await BioDelivery Sciences International, Inc. (NASDAQ:BDSI) to report earnings on November, 14. They expect $-0.26 EPS, up 33.33% or $0.13 from last year’s $-0.39 per share. After $-0.31 actual EPS reported by BioDelivery Sciences International, Inc. for the previous quarter, Wall Street now forecasts -16.13% EPS growth.

BioDelivery Sciences International, Inc. (NASDAQ:BDSI) Ratings Coverage

Out of 5 analysts covering BioDelivery Sciences International (NASDAQ:BDSI), 3 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 60% are positive. BioDelivery Sciences International has been the topic of 9 analyst reports since August 16, 2015 according to StockzIntelligence Inc. FBR Capital maintained BioDelivery Sciences International, Inc. (NASDAQ:BDSI) on Tuesday, November 10 with “Mkt Perform” rating. Cantor Fitzgerald downgraded the shares of BDSI in a report on Wednesday, May 11 to “Hold” rating. The firm earned “Neutral” rating on Tuesday, October 27 by Janney Capital. The firm has “Overweight” rating by Piper Jaffray given on Thursday, May 12. The stock has “Overweight” rating given by Piper Jaffray on Monday, February 8. On Friday, September 23 the stock rating was upgraded by Janney Capital to “Buy”. The stock of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) has “Buy” rating given on Wednesday, November 4 by Cantor Fitzgerald. The rating was maintained by William Blair on Sunday, August 16 with “Buy”. The stock of BioDelivery Sciences International, Inc. (NASDAQ:BDSI) earned “Buy” rating by Roth Capital on Friday, March 11.

According to Zacks Investment Research, “BioDelivery Sciences International is a development-stage biotechnology company that is developing and seeking to commercialize a drug delivery technology designed for a potentially broad base of pharmaceuticals, vaccines and over-the-counter drugs. In general, a drug delivery technology refers to any process, substance, or combination thereof, that delivers drugs into the body.”

Insitutional Activity: The institutional sentiment decreased to 0.57 in Q2 2016. Its down 0.19, from 0.76 in 2016Q1. The ratio dropped, as 30 funds sold all BioDelivery Sciences International, Inc. shares owned while 30 reduced positions. 13 funds bought stakes while 21 increased positions. They now own 29.37 million shares or 23.18% less from 38.23 million shares in 2016Q1.
Alpine Vi Lc accumulated 62,195 shares or 0.07% of the stock. Wells Fargo And Mn owns 8,307 shares or 0% of their US portfolio. Sabby Mngmt Ltd Liability Company owns 785,799 shares or 0.1% of their US portfolio. Bnp Paribas Arbitrage Sa has 0% invested in the company for 18 shares. Armistice Capital Limited Liability, a New York-based fund reported 2.65 million shares. Ameriprise last reported 891,268 shares in the company. Valley Advisers has invested 0.01% of its portfolio in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). Tiaa Cref Investment Limited Liability Corp has invested 0% of its portfolio in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). Condor Cap last reported 0.01% of its portfolio in the stock. The Washington-based Parametric Port Assocs Limited Liability has invested 0% in BioDelivery Sciences International, Inc. (NASDAQ:BDSI). Bancorp Of New York Mellon Corp last reported 0% of its portfolio in the stock. Stephens Incorporated Ar reported 10,000 shares or 0% of all its holdings. Moreover, Morgan Stanley has 0% invested in BioDelivery Sciences International, Inc. (NASDAQ:BDSI) for 92,892 shares. National Bank & Trust Of America De owns 13,152 shares or 0% of their US portfolio. Baker Bros L P has 210,021 shares for 0.01% of their US portfolio.

Insider Transactions: Since August 11, 2016, the stock had 1 buying transaction, and 4 sales for $441,717 net activity. Vasisht Niraj sold $114,360 worth of stock or 47,000 shares. De Paolantonio Ernest Robert sold 14,800 shares worth $36,112. The insider ODONNELL FRANCIS E JR sold $256,500. Another trade for 2,500 shares valued at $6,375 was bought by Feinberg Barry I. STONE WILLIAM B sold 16,000 shares worth $41,120.

More news for BioDelivery Sciences International, Inc. (NASDAQ:BDSI) were recently published by:, which released: “BioDelivery Sciences Remains Undervalued” on October 13, 2016.‘s article titled: “BioDelivery Sciences to Present at the Rodman & Renshaw 18th Annual Global …” and published on September 06, 2016 is yet another important article.

BDSI Company Profile

BioDelivery Sciences International, Inc., incorporated on April 18, 2002, is a specialty pharmaceutical company. The Firm develops and commercializes, either on its own or in partnerships with third parties, applications of approved therapeutics to address unmet medical needs using drug delivery technologies. The Firm develops pharmaceutical products aimed principally in the areas of pain management and addiction. The Company’s products utilize the BioErodible MucoAdhesive (BEMA) drug delivery technology, a small, erodible polymer film for application to the buccal mucosa (the lining inside the cheek). The Company’s United Sates Food and Drug Administration (FDA) approved product, ONSOLIS (fentanyl buccal soluble film), as well as its approved products BUNAVAIL (buprenorphine and naloxone buccal film) buccal film and BELBUCA (buprenorphine) buccal film, utilize BEMA technology.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Reply